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Synthesis of castanospermine 
Abstract 
The diastereoselective synthesis of castanospermine is described in 11 synthetic steps from L-xylose. 
The borono-Mannich reaction between L-xylose, allylamine and (E)-styrene boronic acid gives a 
tetrahydroxy amine with the desired configurations for C-6, C-7, C-8 and C-8a in the target molecule. A 
novel pyrrolo[1,2-c]oxazol-3-one precursor was employed to allow for the control of pi-facial 
diastereoselectivity in an osmium(VIII)-catalysed syn-dihydroxylation (DH) reaction. A regioselective ring-
opening of the cyclic sulfate derivative of the resulting diol then secured the C-1 hydroxyl group of 
castanospermine with the correct configuration. A Mitsunobu cyclization then provided di-O-benzyl 
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Abstract: The diastereoselective synthesis of castanospermine is described in 11 synthetic steps 
from L-xylose.  The borono-Mannich reaction between L-xylose, allylamine and (E)-styrene boronic 
acid gives a tetrahydroxy amine with the desired configurations for C-6, C-7, C-8 and C-8a in the target 
molecule.  A novel pyrrolo[1,2-c]oxazol-3-one precursor was employed to allow for the control of -
facial diastereoselectivity in an osmium(VIII)-catalysed syn-dihydroxylation (DH) reaction. A 
regioselective ring-opening of the cyclic sulfate derivative of the resulting diol then secured the C-1 
hydroxyl group of castanospermine with the correct configuration.  A Mitsunobu cyclization then 




The indolizidine alkaloid castanospermine 1 was first isolated from the seeds of 
Castanospermum australe1 and then from the dry pods of Alexa leiopetala.2 Castanospermine is a 
potent inhibitor of several glucosidases3 and has potential for the treatment of viral infections,4 
cancers,5 and diabetes.6  In addition it shows anti-inflammatory7 and immunosuppressant8 properties. 
Recent in vitro studies have demonstrated that 1 was able to prevent mortality in mice infected with 
dengue virus.9 Because of its unique structure and biological activities many syntheses of 
castanospermine have been reported.10  As part of our program concerned with the synthesis of 
2 
polyhydroxylated indolizidine and pyrrolizidine alkaloids11-19 we report here a 11-step synthesis of 
castanospermine from L-xylose.  This synthesis demonstrates the versatility and flexibility of our 










Figure 1.  Structure of castanospermine (1). 
 
2. Results and Discussion 
The known amino-tetraol 2,17 obtained from the borono-Mannich reaction of L-xylose, allylamine and 
(E)-styrene boronic acid,  was converted to oxazolidin-2-one 3 upon treatment with triphosgene under 
basic conditions (Scheme 1).13,14 The triol 4 was readily converted to its O-trityl derivative 4 in 87% 
yield under standard conditions.17 Under basic O-benzylation reaction conditions17 compound 4 gave a 
mixture of the corresponding di-O-benzyl-oxazolidin-2-one 5 and the oxazin-2-one 6 (Scheme 1).  
These could be separated by column chromatography to provide pure samples of 5 and 6 in yields of 
56% and 22%, respectively, however this separation was difficult. Treatment of 5 with Grubbs’ second 
generation ruthenium catalyst19 gave the pyrrolo[1,2-c]oxazol-3-one 7 in 88% yield.  Alternatively, 7 
could be more readily obtained by treating a mixture of 5 and 6 with Grubbs’ second generation 
ruthenium catalyst followed by a relatively easier separation of 7 (68%) from the pyrrolo[1,2-c]oxazin-
1-one 8 (20%) (Scheme 1). 
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Based on our previous work,13,14,19 and that of Parsons,20,21 we expected that the syn-dihydroxylation 
(DH) of 7 would furnished the corresponding diol with the desired stereochemistry for the synthesis of 
the target alkaloid.  In the event, the osmium(VIII)-catalysed syn-DH of 7 furnished the desired diol 9  
accompanied by 17% of its diastereomeric diol in 84% yield after purification of the crude reaction 
mixture by column chromatography (Scheme 2).  Separation of this mixture by further column 
chromatography gave diastereomerically pure 9 in 60% yield and 6,7-di-epi-9 in 16% yield. The diol 9 
was then converted to the cyclic sulfate 10 in 64% overall yield by first treatment with thionyl chloride 
under basic conditions to give the corresponding cyclic sulfite followed by oxidation at sulfur with 
catalytic ruthenium tetraoxide (RuCl3, NaIO4).
13,22 Regioselective reductive ring-opening of 10 with 
sodium borohydride10(f) in dimethylacetamide (DMA) at rt for 6 h followed by acid hydrolysis of the 
resulting adduct gave the diol 11 in 63% yield in which the O-trityl group had also been cleaved 
(Scheme 2).  Base catalysed hydrolysis of the oxazolidinone ring of 11 under microwave irradiation 
conditions gave the pyrrolidine 12 in 80% yield which was readily separated from the unexpected 
cyclized product, the furan derivative 13 (16% yield). We have not unequivocally proved the 
structure of 13.  However this compound is also produced as a byproduct from the Mitsunobu reaction 
of 12 in Scheme 3. The most likely mechanism for the formation of 13 in the latter reaction is a shown 
in Scheme 3 via initial activation of the primary hydroxyl.  We therefore speculate that 13 arises from 
11 (Scheme 2) via cyclizaion of the incipient alkoxide ion that is generated from collapse of the initial 
tetrahedral intermediate formed from addition of hydroxide ion to the carbonyl group of the 
oxazolidinone moiety of 11. This incipient alkoxide intermediate then attacks the carbon of the 






















































































Attempts to cyclize the amino-triol 12 under Appel cyclization reaction conditions (Ph3P/CBr4/Et3N)
23 
were unsuccessful and a complex mixture of products resulted.  Treatment of 12 under Mitsunobu 
reaction conditions24 produced the desired indolizidine product 14 in 25% yield along with the furan 
1325 (22% yield) and the oxepino[3,2-b]pyrrole 15 (11% yield) (Scheme 3).  These three isomeric 
compounds were readily distinguished by 13C and HMBC NMR experiments.  The structure of the 
indolizidine 14 was clear from the  relatively upfield 13C NMR methylene resonances at   54.2 (C-5) 
and 52.0 (C-2) for the methylenes directly attached to nitrogen. While the downfield methylene 
resonances at  72.0 (C-5’) and  72.2 (C-5) in 13 and 15, respectively were consistent with methylenes 
directly attached to oxygen in a ring system.  HMBC NMR experiments on 13 demonstrated a 3-bond 
correlation between C-2’ and H-5’, such a correlation between the analogous carbon (C-8) and proton 
(H-5) in 15 would not be expected as this would represent a 4-bond correlation. 
Debenzylation of 14 under hydrogenolysis conditions using PdCl2/H2
26 gave castanospermine 1 in 95% 
yield after ion-exchange chromatography (Scheme 3). The 1H and 13C NMR spectral data of this 
compound matched very closely to that reported in the literature.1 The optical rotation of this 
compound []D27  + 82 (c 1.2, H2O) also agreed with that reported (lit.1 []D24  + 79.7 (c 0.93, H2O)). 
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In conclusion we have successfully developed a diastereoselective synthesis of castanospermine 
in 11 synthetic steps from L-xylose using the borono-Mannich reaction to give a tetrahydroxy amine 
with the desired configurations for C-6, C-7, C-8 and C-8a in the target molecule.  A novel pyrrolo[1,2-
c]oxazol-3-one precursor was employed to allow for the control of -facial diastereoselectivity in an 
osmium(VIII)-catalysed syn-dihydroxylation (DH) reaction. A regioselective ring-opening of the cyclic 
sulfate derivative of the resulting diol then secured the C-1 hydroxyl group of castanospermine with the 
correct configuration.  A Mitsunobu cyclization then provided di-O-benzyl castanospermine and 
ultimately the final target alkaloid. This synthesis further demonstrates the versatility and flexibility of 
our earlier synthetic strategy for preparing polyhydroxyindolizidines.17 
 
4. Experimental 
General methods were as described previously.12,13 All 1H NMR spectra were performed at 500 MHz 
and all 13C NMR (DEPT) spectra at 125 MHz in CDCl3 solution, unless otherwise noted.  NMR 
assignments are based on COSY, DEPT and HSQC NMR experiments and sometimes HMBC and 
NOESY experiments. IR spectra were determined as neat samples.  Petrol refers to petroleum spirit bp 
40-60 oC.   
 
(4R,5R)-3-Allyl-5-((1R,2S)-1,2,3-trihydroxypropyl)-4-((E)-2-phenyl-vinyl)-1,3-oxazolidin-2-one 
(3) and its 1,3-dioxolan-2-onyl derivative, (4R,5R)-3-allyl-5-(((4S)-1,3-dioxolan-2-onyl)-
hydroxymethyl)-4-((Z)-2-phenylvinyl)-1,3-oxazolidin-2-one. 
To a solution of the amino alcohol 217 (4.560 g, 15.56 mmol) in dry THF (400 mL) was added 
triethylamine (4.3 mL, 31.13 mmol) and then triphosgene (1.390 g, 4.68 mmol). The mixture was 
stirred at rt for 10 h, followed by the evaporation of all volatiles in vacuo. The residue was suspended 
in water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were 
dried (MgSO4) and filtered then concentrated in vacuo to give a yellow solid. Chromatography of the 
crude product and eluting with 90-100% EtOAc/petrol and then 2% MeOH/EtOAc gave compound 3 
as a white crystalline solid (2.65 g, 53%, Rf = 0.20, 2% MeOH/EtOAc). [α]D
27  -10 (c 4.5, MeOH).  Mp 
8 
141 ºC. IR νmax/cm
-1 3550, 2950, 2914, 1737, 1447, 1094, 1041. MS (ESI+) m/z 320 (M+H+), 100%. 1H 
NMR (CD3OD) δ 3.57 (1H, dd, J = 11.3, 6.3 Hz, H3’), 3.60 (1H, app. ddt, J = 15.7, 6.7, 1.3 Hz, H1’’’), 
3.65 (1H, dd, J = 11.3, 5.3 Hz, H3’), 3.73 (1H, m, H2’), 3.83 (1H, app. t, J = 4.3 Hz, H1’), 4.01 (1H, 
app. ddt, J = 15.7, 4.7, 1.7 Hz, H1’’’), 4.61 (1H, app. t, J = 9.0 Hz, H4), 4.83 (1H, dd, J = 8.5, 4.0 Hz, 
H5),  5.20 (1H, dd, J = 10.0, 1.5 Hz, H3’’’), 5.22 (1H, dd, J = 17.5, 1.0 Hz, H3’’’), 5.79 (1H, m, H2’’’), 
6.38 (1H, dd, J = 16.0, 9.5 Hz, H1’’ ), 6.70 (1H, d, J = 16.0 Hz, H2’’), 7.36 (5H, m, Ar-H).  13C NMR 
(CD3OD) δ 45.5 (CH2), 62.6 (CH), 64.1 (CH2), 70.9 (CH), 73.3 (CH), 78.9 (CH), 118.3 (CH), 124.2 




1,3-oxazolidin-2-one (4).  
To a solution of oxazolidinone 3 (2.42 g, 7.59 mmol) in anhydrous pyridine (40 mL) was added trityl 
chloride (3.17 g, 11.38 mmol). The mixture was stirred for 20 h at rt. The reaction was quenched with 
water (60 mL) then extracted with diethyl ether (3 x 80 mL). The combined organic phases were 
washed with saturated CuSO4 (3 x 90 mL) and brine (90 mL), dried (MgSO4) and evaporated to give a 
yellow oil that was purified by column chromatography (30-50% EtOAc/petrol) to give  compound 4 
as a white foamy solid (3.68 g, 87%, Rf = 0.20, 30% EtOAc/petrol). [α]D
27  -18 (c 4.4, CHCl3). IR 
νmax/cm
-1  3401, 3053, 3027, 2914, 1731, 1448, 1070. MS (ESI+) m/z 579 (M+NH4
+, 100%) ; HRMS 
(ESI+)  calcd for C36H35NO5Na (M+Na
+)  584.2413, found 584.2419. 1H NMR δ 2.57 (1H, br.d, J = 
5.0 Hz, OH1’), 2.82 (1H, br.d, J = 5.5 Hz, OH2’), 3.18 (1H, dd, J = 10.0, 5.5 Hz, H3’), 3.31 (1H, dd, J 
= 9.5, 5.0 Hz, H3’), 3.54 (1H, dd, J = 15.5, 7.5 Hz, H1’’’), 3.90 (1H, br. t, J = 4.0 Hz, H2’), 3.96 (1H, 
br. d, J = 3.5 Hz, H1’), 4.11 (1H, dd, J = 15.8, 6.5 Hz, H1’’’),  4.46 (1H, app. t, J = 9.3, Hz, H4), 4.55 
(1H, dd, J = 8.8, 3.8 Hz, H5), 5.18 (1H, dd, J = 17.3, 1.0 Hz, H3’’’), 5.21 (1H, dd, J = 10.3, <1 Hz, 
H3’’’), 5.74 (1H, m, H2’’’), 6.32 (1H, dd, J = 16.0, 9.5 Hz, H1’’), 6.61 (1H, d, J = 15.5 Hz, H2’’), 
9 
7.39-7.19 ( 20H, m, Ar). 13C NMR δ 44.8 (CH2), 61.1 (CH), 64.4 (CH2), 69.9 (CH), 71.0 (CH),77.3 
(CH), 87.2 (C), 118.7 (CH), 123.0 (CH), 127.1-129.0 (20×Ar-CH), 132.1 (CH), 135.6 (Ar-C), 137.6 
(CH), 143.7 (Ar-C), 157.2 (CO). 
 
(4R,5R)-3-Allyl-5-((1S,2S)-1,2-bis(benzyloxy)-3-(triphenylmethoxy)-propyl)-4-((E)-2-
phenylvinyl)-1,3-oxazolidin-2-one (5), and (4R,5R,6S)-3-allyl-5-(benzyloxy)-6-((S)-1-(benzyloxy)- 
2-(triphenylmethoxy)-ethyl)-4-((E)-2-phenylvinyl)-1,3-oxazinan-2-one (6). 
To a solution of 4 (4.403 g, 7.85 mmol) in dry THF (50 mL) was added 40% NaH in mineral oil (1.20 
g, 19.62 mmol). After H2 evolution had ceased (15 min), benzyl bromide (7.5 mL, 62.79 mmol) and 
tetrabutylammonium iodide (444 mg, 1.18 mmol) were added. The mixture was stirred for 24 h at rt, 
then treated with methanol (10 mL) and triethylamine (6 mL) and stirred for 15 min. All volatiles were 
removed in vacuo and the residue was dissolved in CH2Cl2, filtered through a pad of celite, followed by 
further washings of the solids with CH2Cl2. The filtrate was washed with water and brine and then 
dried (MgSO4) and concentrated to give a yellow oil. The residue was purified by column 
chromatography (20-40% EtOAc/petrol) to yield two compounds, 5 as a yellow oil (3.258 g, 56%) and 
6 as a yellow oil (1.299 g, 22%). Because of the similar polarity of the products (Rf of 5 = 0.60 and Rf 
of 6 = 0.55 in 40% EtOAc/petrol), they were used in the subsequent RCM reaction step without 
separation.   
5: [α]D
26 +52 (c 3.2, CHCl3). IR νmax/cm
-1  3058, 3027, 2945, 2873, 1752, 1450, 1070. MS (ESI+) m/z 
764 (M + Na+, 85%), HRMS (ESI+) calcd for C50H47NO5Na (M + Na
+) 764.3351, found 764.3378. 1H 
NMR (300 MHz) δ 3.32 (1H, dd, J = 16.0, 7.5 Hz, H1’’’), 3.39 (1H, dd, J = 9.5, 5.0 Hz, H3’), 3.44 
(1H, dd, J = 10.0, 5.0 Hz, H3’), 3.58 (1H, app. t, J = 8.0 Hz, H4), 3.75 (1H, m, H2’), 4.01 (1H, J = dd, 
7.5, 3.3 Hz, H1’), 4.08 (1H, app. dd, J = 16.0, 4.5 Hz, H1’’’), 4.13 (1H, d, J = 12.0 Hz, CH2Ph), 4.60 
(1H, d, J = 11.4 Hz, CH2Ph), 4.65 (1H, d J = 12.0 Hz, CH2Ph), 4.79 (1H, app. t, J = 7.4, Hz, H5), 4.85 
(1H, d, J = 11.1 Hz, CH2Ph), 5.06 (1H, d, J = 17.0 Hz, H3’’’), 5.15 (1H, d, J = 10.0 Hz, H3’’’), 5.63 
10 
(1H, m, H2’’’), 5.93 (1H, d, J = 15.5 Hz, H2”), 5.99 (1H, dd, J = 16.0, 9.0 Hz,  H1’’), 7.35-7.09 (30H, 
m, Ar). 13C NMR δ 43.8 (CH2), 59.4 (CH), 60.6 (CH2), 70.7 (CH2), 74.3 (CH2), 74.4 (CH), 76.6 (CH), 
77.2 (CH), 77.4 (CH), 86.6 (C), 117.7 (CH2), 121.0 (CH), 126.1-128.7 (30×Ar-CH) 131.9 (CH), 134.5, 
(Ar-C), 136.8 (CH), 137.4 (Ar-C), 137.7 (Ar-C), 143.2 (3 × Ar-C), 156.8 (CO). 
6: [α]D
26 +37 (c 1.2, CHCl3). MS (ESI+) m/z 764 (M+Na
+, 100%)  HRMS (ESI+)  calc. for 
C50H47NO5Na (M+Na
+) 764.3352,  found 764.3364. 1H NMR (300 MHz) δ 2.92 (1H, dd, J = 10.7, 2.9 
Hz, H2’), 3.34 (1H, app. ddt, J = 15.5, 7.7, 1.1 Hz, H1’’’), 3.45 (1H, app. t, J = 1.8 Hz, H5), 3.57 (1H, 
d, J = 10.8 Hz, CH2Ph), 3.70 (1H, dd, J = 10.5, 1.8 Hz, H2’), 3.90 (1H, app dt, J = 7.8, 1.8 Hz, H1’), 
4.08 (1H, app. dt, J = 6.3, 1.7 Hz, H4), 4.24 (1H, d, J = 11.1 Hz, CH2Ph), 4.60-4.52 (1H, m, H1’’’), 
4.70 (1H, d, J = 11.4 Hz, CH2Ph), 4.84 (1H, d, J = 11.4 Hz, CH2Ph), 4.93 (1H, dd, J = 7.8, 1.5 Hz, H6), 
5.12 (1H, dd, J = 10.2, 1.5 Hz, H3’’’), 5.16 (1H, dd, J = 17.4, 1.5 Hz, H3’’’), 5.77 (1H, m, H2’’’), 5.93 
(1H, dd, J = 15.9, 6.3 Hz, H1’’), 6.54 (1H, dd, J = 15.9, 1.5 Hz, H2’’), 7.57-7.06 (30H, m, Ar). 13C 
NMR δ 50.0 (CH2), 57.9 (CH), 62.2 (CH), 71.6 (CH2), 73.2 (CH), 73.9 (CH2), 77.6 (CH), 79.3 (CH), 
86.5 (C), 118.0 (CH2), 125.2 (CH), 127.2-129.1 (30×Ar-CH), 132.9 (CH), 134.1 (CH), 135.7 (Ar-C), 
137.2 (Ar-C), 138.8 (Ar-C), 143.6 (3 × Ar-C), 153.2 (CO). 
 
(1R,7aR)-1-((1S,2S)-1,2-Bis(benzyloxy)-3-(triphenylmethoxy)propyl)-1,7a-dihydropyrrolo[1,2-
c]oxazol-3(5H)-one (7), and (3S,4R,4aR)-4-(benzyloxy)-3-((S)-1-(benzyloxy)-2-
(triphenylmethoxy)-ethyl)-4,4a-dihydro-3H-pyrrolo[1,2-c] [1,3]oxazin-1(7H)-one (8). 
Method 1: Synthesis of 7 from pure 6. 
Grubbs’ II catalyst (105.2 mg, 0.124 mmol) was added to a solution of oxazolidinone 6 (918.8 mg, 
1.240 mmol) in dry CH2Cl2 (150 mL) under nitrogen. The mixture was heated at reflux for 48 h, 
followed by cooling to rt and then removal of the solvent in vacuo to give a brown oil. The residue was 
purified by column chromatography (20-50% EtOAc/petrol) to give compound 7 (695.1 mg, 88%, Rf = 
0.26, 30% EtOAc/petrol) as a white foamy solid.  
11 
Method 2: Synthesis of 7 and 8 from a mixture of 6 and 7. 
Grubbs’ II catalyst (199 mg, 0.234 mmol) was added to a solution of the mixture of 6 and 7 (2.383 g, 
3.22 mmol), obtained above from 4, in dry CH2Cl2 (350 mL) under nitrogen. The mixture was heated at 
reflux for 48 h, followed by cooling to rt and then removal of the solvent in vacuo to give a brown oil. 
The residue was purified by column chromatography (20-50% EtOAc/petrol) to give compound 7 
(1.403 g, 68%, Rf = 0.26, 30% EtOAc/petroleum ether) as a white foamy solid, and 8 (412.4 mg, 20%, 
Rf = 0.07, 30% EtOAc/petrol) as a white foamy solid.  
7: [α]D
25  +13 (c 4.5, CHCl3). IR νmax/cm
-1  3063, 3027, 2945, 2868, 1696, 1125, 1070, 1029. MS 
(ESI+) m/z 660 (M+Na+, 43%), HRMS (ESI+) calcd for C42H39NO5Na (M+Na
+) 660.2726, found 
660.2712. 1H NMR δ 3.43 (1H, dd, J = 10.0, 4.8 Hz, H3’), 3.52 (1H, dd, J = 10.0, 5.0 Hz, H3’), 3.66-
3.61 (1H, m, H5), 3.69-3.70 (2H, m, H1’, H2’), 4.04-4.08 (1H, m, H7a), 4.22-4.27 (1H, m, H5), 4.35 
(1H, d, J = 11.5 Hz, CH2Ph), 4.58 (1H, d, J = 11.0 Hz, CH2Ph), 4.64 (1H, d, J = 11.5 Hz, CH2Ph), 4.71 
(1H, d, J = 11.5 Hz, CH2Ph), 4.77 (1H, dd, J = 8.0, 6.0 Hz, H1), 5.65 (1H, app. dd, J = 6.0, 1.0 Hz, 
H6), 5.84 (1H, app. dd, J = 6.0, 1.5 Hz, H7), 7.43-7.12 (25H, m, Ar). 
13C NMR δ 54.7 (CH2), 62.5 (CH2), 67.0 (CH), 72.6 (CH2), 74.6 (CH), 77.1 (CH), 78.3 (CH), 79.0 
(CH), 87.4 (C), 126.2 (CH), 127.4-128.8 (25×Ar-CH), 131.7 (CH), 138.1(Ar-C), 138.2 (Ar-C), 144.0 
(3 × Ar-C), 162.2 (CO). 
8: [α]D
27  +67 (c 5.15, CHCl3). IR νmax/cm
-1  3052, 3027, 2924, 2863, 1685, 1105, 1096. MS (ESI+) m/z 
660 (M+Na+, 42%), HRMS (ESI+) calcd for C42H39NO5 (M
+) 637.2828, found 637.2811. 1H NMR δ 
3.51 (1H, dd, J = 10.0, 7.0 Hz, H2’), 3.54 (1H, dd, J = 10.0, 6.0 Hz, H2’), 3.60 (1H, dd, J = 10.0, 6.0 
Hz, H4), 3.86 (1H, ddd, J = 7.2, 6.0, 1.5 Hz, H1’), 4.03 (1H, ddt, J = 16.0, 4.5, 1.5 Hz, H7), 4.40 (1H, 
ddt, J = 16.0, 4.5, 1.5 Hz, H7), 4.45 (1H, d, J = 11.5 Hz, CH2Ph), 4.52 (1H, dd, J = 9.8, 1.5 Hz, H4a), 
4.57 (1H, d, J = 11.5 Hz, CH2Ph), 4.59 (1H, d, J = 11.5 Hz, CH2Ph), 4.60 (1H, d, J = 11.5 Hz, CH2Ph), 
4.61(1H, dd, J = 6.0, 1.0 Hz, H3), 5.84 (2H, br. m, H5, H6), 7.43-7.20 (25H, m, Ar). 13C NMR δ 55.4 
12 
(CH2), 63.0 (CH), 63.1 (CH2), 72.5 (CH2), 73.1 (CH2), 74.3 (CH), 75.4 (CH), 75.6 (CH), 87.7 (C), 
127.3-128.9 (25×Ar-CH), 127.9 (HC=CH), 137.3 (Ar-C), 138.4 (Ar-C), 144.2 (3 ×Ar-C), 152.1 (CO).  
 
(1R,6S,7R,7aR)-1-((1S,2S)-1,2-Bis(benzyloxy)-3-(triphenylmethoxy)propyl)-tetrahydro-6,7-
dihydroxypyrrolo[1,2-c]oxazol-3(1H)-one (9) and (1R,6R,7S,7aR)-1-((1S,2S)-1,2-bis(benzyloxy)-3-
(triphenylmethoxy)-propyl)-tetrahydro-6,7-dihydroxypyrrolo[1,2-c]oxazol-3(1H)-one (6,7-di-epi-
9). 
To a solution of 7 (1.403 g , 2.203 mmol) in acetone (13.2 mL) and water (8.8 mL) was added 
potassium osmate dihydrate (57 mg, 0.15 mmol) and 4-morpholine N-oxide (516 mg, 4.41 mmol). The 
mixture was stirred at rt for 48 h followed by evaporation of all the volatiles to give a black oil. 
Purification by column chromatography (70–90% EtOAc/petrol) gave a mixture of diastereoisomeric 
dihydroxy products, 9 and 6,7-di-epi-9, as a white foamy solid (1.242 g, 84%, d.r. = 83 : 17). The 
isomers were separated using 2% MeOH/CH2Cl2 as an eluent on a silica gel column (1 cm diameter × 
30 cm long) to give the pure compound 9 (894 mg, 60%) and compound 6,7-di-epi-9 (248 mg, 16%) 
(Rf of 9 = 0.33 and Rf of 6,7-di-epi-9 = 0.27, 2% MeOH/CH2Cl2). 
9: [α]D
27 +43 (c 3.5, CHCl3). IR νmax/cm
-1  3411, 3058, 3027, 2914, 2848, 1734, 1445, 1093, 1055 
MS (ESI+) m/z 694 (M+Na+, 100%) HRMS (ESI+) calcd for C42H42NO7 (M+H
+), 672.2961  found 
672.3005. 1H NMR δ 2.57 (br, OH), 2.94 (1H, dd, J = 8.0, 2.0 Hz, H7a), 3.40 (1H, dd, J = 10.5, 4.8 Hz, 
H3’), 3.36 (1H, dd, J = 11.5, 8.0 Hz, H5), 3.29 (1H, dd, J = 11.5, 7.5 Hz, H5), 3.54-3.55 (2H, m, H3’, 
H7), 3.76, dd, J = 9.5, 5.0 Hz, H2’), 4.14 (1H, m, H6), 4.32 (1H, dd, J = 6.0, 4.5 Hz, H1’), 4.41 (1H, d, 
J = 12.0 Hz, CH2Ph), 4.64 (1H, dd, J = 7.5, 6.0 Hz, H1), 4.71 (1H, d, J = 11.0 Hz, CH2Ph), 4.73 (1H, d, 
J = 12.0 Hz, CH2Ph), 4.76 (1H, d, J = 11.0 Hz, CH2Ph), 7.44-7.18 (25H, m, Ar). 
13C NMR δ 50.6 
(CH2), 62.6 (CH2), 64.6 (CH), 70.8 (CH), 72.3 (CH2), 74.1 (CH), 75.0 (CH2), 76.6 (CH), 76.6 (CH), 
77.4 (CH), 87.4 (C), 127.5-129.0 (25×Ar-CH ), 137.2 (Ar-C), 138.0 (Ar-C), 144.0 (3 × Ar-C), 162.1 
(CO).   
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6,7-di-epi-9: [α]D
24  +24 (c 1.2, CHCl3). IR νmax/cm
-1  3412, 3058, 3027, 2930, 1731, 1447, 1095, 1053. 
MS (ESI+) m/z 694 (M+Na+, 100%). HRMS (ESI+) calcd for C42H42NO7 (M+H
+), 672.2961  found 
672.3020.  1H NMR δ 2.49 (1H, br, OH), 3.08 (1H, dd, J = 12.8, 1.8 Hz, H5), 3.34 (1H, dd, J = 9.0, 7.0 
Hz, H7a), 3.44 (1H, dd, J = 10.0, 5.5 Hz, H3’), 3.53 (1H, dd, J = 10.0, 5.0 Hz, H3’), 3.81 (1H, dd, J = 
13.0, 5.5 Hz, H5), 3.83 (1H, m, H7), 3.96 (1H, dd, J = 8.0, 3.5 Hz, H1’), 4.08-4.09 (2H, m, H2’, H6), 
4.41 (1H, d, J = 12.0 Hz, CH2Ph), 4.53 (1H, d, J = 11.0 Hz, CH2Ph), 4.70 (1H, d, J = 11.5 Hz, CH2Ph), 
4.71 (1H, d, J = 11.5 Hz, CH2Ph), 4.83 (1H, app. t, J = 7.5 Hz, H1), 7.44-7.14 (m, 25H), Ar). 
13C NMR 
δ 52.7 (CH2), 62.2 (CH2), 63.5 (CH), 70.0 (CH), 71.4  (CH), 72.5 (CH2), 74.7 (CH), 76.2 (CH), 76.8 
(CH), 77.2 (CH), 87.7(C),  127.5-129.1 (25×Ar-CH), 137.2 (Ar-C), 137.8 (Ar-C), 143.7 (3 × Ar-C), 
161.0 (CO). 
 
(3aR, 3bS, 4R, 8aS)-Tetrahydro-4-((1S,2S)-1,2-bis(benzyloxy)-3-triphenylmethoxy)-propyl)-2,2-
dioxide,5H,4H-1,3,2-dioxathiolo[3,4]pyrrolo[1,2-c]oxazol-6-one (10). 
To a solution of 9 (1.207 g, 1.80 mmol) in dry CH2Cl2 (40 mL) was added triethylamine (4 mL, 
28.78 mmol) and thionyl chloride (0.2 mL, 2.70 mmol). The mixture was stirred for 48 h at rt, and then 
water (50 mL) was added to the mixture. The aqueous layer was extracted with CH2Cl2 (3 x 100 mL). 
The combined extracts were washed with brine and dried (MgSO4) then evaporated under reduced 
pressure to give a brown foamy solid. The crude cyclic sulfite was used for the next step without 
further purification. The crude obtained above was dissolved in 50 mL of a solution of 
CCl4/CH3CN/H2O (2 : 3 : 2, v/v/v) then NaIO4 (1.539 g, 7.12 mmol) and RuCl3.3H2O (23.5 mg, 0.09 
mmol) were added. The mixture was stirred for 3 h at rt and then diluted with diethyl ether (80 mL). 
The organic layer was filtered through a pad of celite. The filtrate was washed with brine and dried 
(MgSO4). The solvent was removed in vacuo then purified by column chromatography (30-70% 
EtOAc/petrol) to give compound 10 (849 mg, 64%, Rf = 0.49, 50% EtOAc/petrol) as a white foamy 
solid.  [α]D
27 +30.6 (c 7.5, CHCl3). IR νmax/cm
-1  3050, 3020, 2935, 2850, 1761, 1349, 1173, 1075. MS 
14 
(ESI-) m/z 732 (M-H+, 100%) HRMS (ESI+) calcd for C42H39NO9SNa (M+Na
+) 756.2243, found 
756.2297. 1H NMR δ 3.15 (1H, dd, J = 15.0, 5.5 Hz, H8)  3.30 (1H, dd, J = 7.0, 3.5 Hz, H3b), 3.50-
3.55 (2H, m, 2 x H3’), 3.56-3.60 (1H, m, H2’), 4.13 (1H, dd, J = 14.5, 1.0 Hz, H8), 4.26 (1H, dd, J = 
9.5, 4.0 Hz, H1’), 4.29 (1H, d, J = 11.5 Hz, CH2Ph), 4.54 (1H, d, J = 11.5 Hz, CH2Ph), 4.58 (1H, d, J = 
11.5 Hz, CH2Ph), 4.80 (1H, dd, J = 5.5, 3.5 Hz, H3a), 4.84 (1H, d, J = 11.5 Hz, CH2Ph), 5.03-5.05 (2H, 
m, H4, H8a), 7.31 (25H, m, Ar-H). 13C NMR δ 50.2 (CH2), 61.5 (CH2), 63.5 (CH), 72.3 (CH2), 74.3 
(CH2), 74.9 (CH), 77.0 (CH), 77.8 (CH), 83.6 (CH), 84.3 (CH), 87.8 (C), 127.3-129.0 (25×Ar-CH), 




To a solution of 10 (689 mg, 0.940 mmol) in anhydrous N,N-dimethylacetamide (2.5 mL) was added 
NaBH4 (62 mg, 1.410 mmol). The reaction was stirred under nitrogen at rt for 6 h, then the N,N-
dimethylacetamide was removed under reduced pressure and the residue was suspended in THF (30 
mL). Water (1 mL) followed by concentrated H2SO4 (0.5 mL) was added, and the suspension became a 
clear solution. The solution was stirred for 48 h at rt followed by the addition of water (20 mL). The 
mixture was extracted with EtOAc (3 x 30 mL) and the combined extracts were washed with brine, 
dried (MgSO4) and concentrated. The residue was purified by column chromatography (5-10% 
MeOH/EtOAc) to give compound 11 (248 mg, 63%, Rf = 0.40, 8% MeOH/EtOAc) as a white foamy 
solid. [α]D
28 +19 (c 16.6, CHCl3). IR νmax/cm
-1  3426, 3050, 2950, 2840, 1732, 1075, 1052. MS (ESI+) 
m/z 414 (M+H+, 100%).  HRMS (ESI+) calcd for C23H28NO6 (M+H
+)  414.1917, found 414.1926. 1H 
NMR δ 1.74 (1H, dddd, J = 13.5, 10.0, 10.0, 3.5 Hz, H6), 1.93 (1H, ddd, J = 13.5, 8.0, 2.0 Hz, H6), 
3.11 (1H, br. d, J = 9.5 Hz, H7a), 3.14 (1H, dd, J = 7.5, 2.0 Hz, H5), 3.68 (1H, m, H5), 3.78-3.81 (2H, 
m, H2’, H3’), 3.89 (1H, dd, J = 11.0, 3.5 Hz, H3’), 3.93 (1H, app. br. s, H7), 4.20 (1H, app. t, J = 4.5 
Hz, H1’), 4.54 (1H, d, J = 12.0 Hz, CH2Ph), 4.72 (1H, d, J = 11.5 Hz, CH2Ph), 4.75 (1H, d, J = 11.0 
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Hz, CH2Ph), 4.79 (1H, d, J = 11.0 Hz, CH2Ph), 4.94 (1H, dd, J = 7.0, 5.0 Hz, H1), 7.33 (10H, m Ar-H). 
13C NMR δ 34.5 (CH2), 43.8 (CH2), 61.1 (CH2), 67.2 (CH), 70.1 (CH), 72.3 (CH2), 74.5 (CH2), 76.4 
(CH), 76.7 (CH), 77.7 (CH), 128.4-129.0 (10×Ar-CH) 137.0 (Ar-C), 137.8 (Ar-C), 162.9(CO). 
 
  
 (2S,3S)-2-((1R,2S,3S)-2,3-Bis(benzyloxy)-1,4-dihydroxybutyl)-pyrrolidin-3-ol (12) and (2R,3S)-2-
((2R,3S,4S)-3,4-bis(benzyloxy)-tetrahydrofuran-2-yl)pyrrolidin-3-ol (13). 
Compound 11 (65.4 mg, 0.16 mmol) was dissolved in MeOH (20 mL) and then a solution of NaOH 
(63.2 mg, 1.58 mmol) in water (5 mL) was added. The mixture was placed in a teflon tube with a 100 
bar pressure cap, then heated in a CEM Discover microwave reactor with constant temperature heating 
at 110 ºC for 2 h. After cooling the mixture was poured into water (50 mL), then extracted with EtOAc 
(4 x 30 mL). The combined organic extracts were dried (MgSO4), filtered and evaporated in vacuo to 
give a semisolid. The pure products were obtained by column chromatography (10:1:0.5; EtOAc: 
MeOH:NH4OH), which gave the desired compound 12 (49 mg, 80%, Rf = 0.33, 10:1:0.5 
EtOAc:MeOH:NH4OH), as a clear oil, and product 13 (10 mg, 16%, Rf = 0.44, 10:1:0.5 
EtOAc:MeOH:NH4OH) as a white solid.   
12: [α]D
27 +32 (c 7.5, CHCl3). MS (ESI+) m/z 388 (M+H
+, 100%), HRMS (ESI+) calcd for C22H30NO5 
(M+H+) 388.2128, found 388.2128. 1H NMR (CD3OD) δ 1.69 (1H, m, H4), 1.84 (1H, dd, J = 13.5, 8.0 
Hz, H4), 2.71 (1H, dd, J = 7.5, 2.5 Hz, H2), 3.06 (1H, app. dt, J = 10.5, 2.0 Hz, H5), 3.54 (1H, ddd, J = 
10.5, 9.5, 8.0 Hz, H5), 3.94 (1H, app. t, J = 2.5 Hz, H3), 4.00 (1H, app. dt, J = 6.0, 2.5 Hz, H3’), 
4.21(1H, dd, J = 10.5, 6.0 Hz, H4’), 4.35 (1H, dd, J = 11.0, 5.5 Hz, H4’), 4.52 (1H, dd, J = 9.0, 2.5 Hz, 
H2’), 4.56 (1H, d, J = 12.0 Hz, CH2Ph), 4.63 (1H, d, J = 11.0 Hz, CH2Ph), 4.77 (1H, d, J = 11.5 Hz, 
CH2Ph), 4.81 (1H, dd, J = 9.0, 7.5 Hz, H1’), 4.83 (1H, d, J = 10.5 Hz, CH2Ph), 7.37 (10H, m, Ar-H).
 
13C NMR (CD3OD)  δ 34.8 (CH2), 43.2 (CH2), 65.4 (CH), 66.3 (CH2), 69.4 (CH), 71.5 (CH2), 74.6 
(CH), 74.9 (CH2), 76.8 (CH), 78.9 (CH),127.8-128.5 (10×Ar-CH), 138.0 (Ar-C), 138.4 (Ar-C). 
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13: [α]D
28 +21 (c 9.4, CHCl3).  IR νmax/cm
-1  3450, 3057, 3027, 2930, 2868, 1614, 1454, 1096, 1073. 
MS (ESI+) m/z 370 (M+H+, 100%). HRMS (ESI+) calcd for C22H28NO4 (M+H
+) 370.2018, found 
370.2010. 1H NMR δ 1.81 (1H, m, H4), 1.97 (1H, m, H4), 2.87 (1H,m, H5), 3.05 (1H, app. t, J = 5.0 
Hz, H2), 3.21 (1H, m, H5), 3.90 (1H, dd, J = 10.5, 4.5 Hz. H5’), 4.08-4.01 (3H, m, H2’, H4’, H5’), 
4.15 (1H, br d, J = 5.0 Hz, H3’), 4.23 (1H, m, H3), 4.50 (1H, d, J = 12.5 Hz, CH2Ph), 4.54 (1H, d, J = 
12.0 Hz, CH2Ph), 4.57 (1H, J = 12.0 Hz, CH2Ph), 4.61 (1H, d, J = 11.5 Hz, CH2Ph), 7.39 (10H, m, Ar-
H). 13C NMR (CDCl3) δ 35.4 (CH2, C4), 44.7 (CH2, C5), 65.5 (CH, C2), 71.6 (C4’-OCH2Ph), 72.0 
(CH2, C5’), 72.5 (C3’-OCH2Ph), 73.4 (CH, C3), 83.0 (CH, C4’), 83.3 (CH, C2’), 86.1 (CH, C3’), 137.4 
(Ar-C), 137.6 (Ar-C).  
 
 (1S,6S,7S,8R,8aS)-6,7-Bis(benzyloxy)-octahydroindolizine-1,8-diol (14) and (3aS,6S,7S,8R,8aS)-
6,7-bis(benzyloxy)-octahydro-1H-oxepino-[3,2-b]pyrrol-8-ol (15). 
To a solution of 12 (49.2 mg, 0.13 mmol) in dry THF (2 mL) was added triphenylphosphine (47 mg, 
0.18 mmol) and diisopropyl azodicarboxylate (36 mg, 0.18 mmol) at 0 ºC. The mixture was stirred at 0-
5 ºC for 12 h, then the volatiles were removed in vacuo to give an oil. The pure products were obtained 
by column chromatography (100% EtOAc and 8.4:1.4:0.2; EtOAc:MeOH:NH4OH), which gave the 
major compound 14 (11.5 mg, 25%, Rf = 0.47, 8.4:1:4.0.2 EtOAc:MeOH:NH4OH)  as a clear oil and 
compound 13 (10 mg, 22% Rf = 0.15, 8.4:1:4.0.2 EtOAc:MeOH:NH4OH or  Rf = 0.44, 10:1:0.5 
EtOAc:MeOH:NH4OH), as a white solid, as well as compound 15 (5.0 mg, 11%, Rf = 0.27, 8.4:1:4.0.2 
EtOAc:MeOH:NH4OH) as a white solid. 
14: [α]D
27 +71 (c 2.5, CHCl3). IR νmax/cm
-1  3360, 3000, 2940, 2868, 1662, 1091, 1075. MS (ESI+) m/z 
370 (M+H+, 100%), HRMS (ESI+) calcd for C22H28NO4 (M+H
+) 370.1135, found 370.1130. 1H NMR 
δ 1.74 (1H, m, H2), 1.85 (1H, dd, J = 10.0, 4.5 Hz, H8a), 1.94 (1H, app. t, J = 9.8 Hz, H5), 2.12 (1H, 
app. q, J = 9.0   Hz, H3), 2.33 (1H, m, H2), 3.08 (1H, app. dt, J = 9.0, 2.5 Hz, H3), 3.29 (1H, dd, J = 
9.0, 5.5 Hz, H7), 3.34 (1H, app. t, J = 9.8 Hz, H5), 3.62 (1H, m, H6), 3.76 (1H, app. t, J = 9.5 Hz, H8), 
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4.30 (1H, m, H1), 4.62 (1H, d, J = 11.5 Hz, CH2Ph), 4.66 (1H, d, J = 11.5 Hz, CH2Ph), 4.87 (2H, br.s., 
CH2Ph), 7.30 (10H, m, Ar-H). 
13C NMR δ 33.4 (CH2, C2), 52.0 (CH2, C3), 54.2 (CH2, C5), 69.4 (CH, 
C8), 69.8 (CH, C1), 72.5 (C7-OCH2Ph), 72.8 (CH, C8a), 75.1 (C6-OCH2Ph), 78.8 (CH, C8), 87.3 (CH, 
C7), 127.2-128.1 (10×Ar-CH ), 138.4(Ar-C), 138.8(Ar-C). 
15: [α]D
27 + 45 (c 2.3, CHCl3). IR νmax/cm
-1  3288, 2904, 2842, 1665, 1091, 1075.  MS (ESI+) m/z 370 
(M+H+, 100%). 1H NMR δ 1.89 (1H, m, overlapped with OH and NH, H3), 1.95 (1H, m, overlapped 
with OH and NH, H3), 2.93 (1H, m, H2), 3.15 (1H, m, H2), 3.35 (1H, dd, J = 8.8, 3.8 Hz, H8a), 3.83 
(1H, dd, J = 9.8, 1.8 Hz, H5), 4.09-4.20 (4H, m, H5, H6, H7, H8), 4.47 (1H, m, H3a), 4.48 (1H, d, J = 
12.0 Hz, CH2Ph), 4.53 (1H, d, J = 12.0 Hz, CH2Ph), 4.55 (1H, d, J = 11.5 Hz, CH2Ph), 4.63 (1H, d, J = 
11.5 Hz, CH2Ph), 7.30 (10H, m, Ar-H). 
13C NMR δ 34.9 (CH2, C3), 44.9 (CH2N, C2), 61.5 (CHN, C8), 
71.7 (CH2Ph), 72.2 (CH2, C5), 72.3 (CH2Ph), 73.2 (CH, C3a), 80.3 (CH, C8), 81.9 (CH, C7), 82.5 (CH, 
C6), 127.9-128.8 (10×Ar-CH), 137.9 (Ar-C), 138.0 (Ar-C). 
 
(1S,6S,7R,8R,8aS)-Octahydroindolizine-1,6,7,8-tetraol (castanospermine) (1) 
The indolizidine 14 (6.4 mg, 0.173 mmol) was dissolved in methanol (1 mL), then PdCl2 (2.4 mg, 
0.013 mmol) was added. The mixture was stirred under an atmosphere of H2 (balloon) for 1 h at rt, 
before the mixture was filtered through a plug of cotton wool. The filtrates were evaporated in vacuo, 
then the residue was dissolved in water (1 mL) and applied to a column of DOWEX-1-basic ion 
exchange resin. Elution with water (30 mL) followed by evaporation of the eluent in vacuo gave the 
title product castanospermine, 1, (3.1 mg, 95%) as a colourless solid.  Mp 206-208 oC (lit.1 212-215 
oC). []D27  + 82 (c 1.2, H2O) (lit.1 []D24  + 79.7 (c 0.93, H2O)). Rf 0.18 (96 : 4 EtOH: aqueous NH3). 
ESI+ m/z 190 (M+H+, 100%). 1H NMR (D2O, HOD ref. at 4.79 ppm)  1.72 (1H, dddd, J2,2 = 14, 
J2,3 = 8.5, J2,3 = 8.5, J2,1 = 1.8, H2), 2.03 (1H, dd, J8a,8 = 10, J8a,1 = 4.5, H8a), 2.07 (1H, t, J5,5 = 
J5,6 = 10.5, H5), 2.23 (1H, q, J3,2 = J3,3 = J3,2  = 9.5, H3), 2.35 (1H, dddd, J2,2 = 14, J2,3 =, 
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9.5, J2,1 = 7.5, J2,3 = 2.5, H2), 3.09 (1H, ddd, J3,3 = J3,2 = 9, J3,2 = 2.5, H3), 3.19 (1H, dd, 
J5,5 = 10.5, J5,6 = 5, H5), 3.34 (1H, t, J7,8 = J6,7 = 9.5, H7), 3.61 (1H, t J8,8a = J8,7 = 9.5, H8), 3.63 
(1H, ddd, J6,5 = 10.5, J6,7 = 9.5, J6,5 = 5, H6), 4.42 (1H, ddd, J1,2 = 7, J1,8a = 4.5, J1,2 = 1.8, H1). 
13C 
NMR (D2O, internal reference, acetone at 30.89 ppm)  79.3 (CH, C7), 71.7 (CH, C8a), 70.4 (CH, C8), 
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